Graves orbitopathy: update on diagnosis and therapy

Area of Science:

• Ophthalmology
• Endocrinology
• Immunology

Background:

• Graves orbitopathy (GO) is the most common extrathyroidal manifestation of Graves disease.
• It is an inflammatory autoimmune condition affecting orbital tissues, leading to potential vision impairment.
• GO presents a significant diagnostic and therapeutic challenge despite advances in understanding its pathogenesis.

Purpose of the Study:

• To review the classification, current management strategies, and emerging therapies for Graves orbitopathy.
• To highlight the importance of disease activity classification for guiding treatment decisions.
• To discuss the role of lifestyle modifications and various treatment modalities in managing GO.

Main Methods:

• Review of current literature on Graves orbitopathy pathogenesis, diagnosis, and treatment.
• Classification of GO based on disease activity and severity.
• Discussion of therapeutic interventions ranging from conservative measures to surgical and novel approaches.

Main Results:

• GO incidence varies by sex, with higher rates in women.
• Disease classification aids in determining appropriate treatment.
• Mild GO may respond to symptomatic treatments, while moderate-to-severe cases require systemic therapies or surgery.

Conclusions:

• Effective management of Graves orbitopathy requires individualized treatment strategies based on disease severity and activity.
• Smoking cessation and euthyroidism are crucial adjuncts to medical and surgical interventions.
• Investigational therapies like rituximab offer future promise for addressing the underlying immunological basis of GO.